Investor relations

With the marketing approval for Sedaconda (isoflurane) in 15 EU countries and a great interest in inhaled sedation and our products, Sedana Medical is well-positioned for the future.

We are well on the way to the vision of making inhaled sedation a standard therapy in critical care.

The Share

See More

Press Releases

Sedana Medical submits IND for US clinical trials


Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an In…

Sedana Medical AB (publ), Third Quarter Report 2021


Sedaconda (isoflurane) approved in 11 European markets

Sedana Medical’s Nomination committee appointed


Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General…

View All Press Releases

Financial Calendar

Year-End report 2021 17 February 2022 07:00
Annual report 2021 07 April 2022 07:00

See More